KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $10.6 million.

  • Biomarin Pharmaceutical's Depreciation and Depletion fell 275.23% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.9 million, marking a year-over-year increase of 262.58%. This contributed to the annual value of $46.6 million for FY2024, which is 1563.28% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Depreciation and Depletion is $10.6 million, which was down 275.23% from $10.6 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Depreciation and Depletion registered a high of $14.1 million during Q1 2025, and its lowest value of $8.7 million during Q3 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's median Depreciation and Depletion value was $10.7 million (recorded in 2023), while the average stood at $10.9 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first plummeted by 4191.45% in 2021, then soared by 2298.85% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Depreciation and Depletion (Quarter) stood at $10.4 million in 2021, then fell by 16.35% to $8.7 million in 2022, then grew by 22.99% to $10.7 million in 2023, then rose by 8.41% to $11.6 million in 2024, then decreased by 8.62% to $10.6 million in 2025.
  • Its Depreciation and Depletion stands at $10.6 million for Q3 2025, versus $10.6 million for Q2 2025 and $14.1 million for Q1 2025.